UNSPSC 51352428: Estradiol/testosterone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352428 Estradiol/testosterone, a Commodity code, encompasses hormone replacement and endocrine therapeutic pharmaceuticals that state and local health agencies procure through cooperative purchasing vehicles and direct manufacturer or wholesaler supply chains. State and local governments under this code acquire generic and brand-name estradiol and testosterone products for distribution through state health benefit programs, Medicaid agencies, and employee health plans. The work involves establishing supply agreements with pharmaceutical manufacturers, negotiating pricing structures with authorized wholesalers, and managing product fulfillment to state health systems and participating jurisdictions.

State agencies and multistate cooperative purchasing alliances dominate solicitation activity under this code. The Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota Department of Administration's Office of State Procurement, are recent repeat buyers. The MMCAP RFP (S1070000015802), posted January 20, 2026, with a March 26, 2026 response deadline, seeks generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities, including Oregon, with pricing competitiveness weighted at 75 percent and mandatory compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act; awarded vendors must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with products effective July 1, 2026. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement of direct-contracting supply arrangements. Activity concentrates in Texas and Minnesota, with secondary participation from Oregon through cooperative purchasing participation. No recent opportunities specify dollar values or estradiol/testosterone-specific procurement, though the MMCAP structure indicates multi-award capability across therapeutic categories and pricing-model flexibility (flat price, net price, WAC-minus).